Geoff is an Executive Director at Amgen, Inc. where he leads an experienced and highly cross-functional team dedicated to the topic of biosimilars (biological medicines claiming similarity to an approved product). Geoff is accountable for aspects of Amgen’s strategic planning related to biosimilars and integrating U.S. Policy, regulatory, communications and business activities. He comes to this position with a deep experience in biosimilars as his most recent role was Director of Amgen’s Regulatory Biosimilar Team with significant focus on establishment of the U.S. Biosimilar pathway as authorized by Congress in 2010 in the Biologics Price Competition and Innovation Act (BPCIA). As Amgen considers the implications of a legal and regulatory pathway for biosimilars, Geoff’s team has been able to synthesize the scientific and technical aspects of regulatory policies and guidelines for biologics with innovator experiences from Europe and the multifaceted aspects of the U.S. heath care environment. Geoff joined Amgen in 2007 and his leadership roles have afforded the opportunity to work alongside many business functions including government affairs, manufacturing & quality, commercial operations and law. His team spans Amgen sites in Washington D.C., Boulder, Colorado and Thousand Oaks, California and he works closely with Amgen’s European, Canadian and emerging market interests. Geoff holds a Bachelors of Science degree from the U.S. Naval Academy at Annapolis and a Masters of Business Administration from the University of Maryland. He is a Paul Harris Fellow and is married with two children.